Article Text

Download PDFPDF
Randomised controlled trial
The RTS,S/AS01 vaccine continues to show modest protection against malaria in African infants and children
  1. Philip J Rosenthal
  1. Department of Medicine, University of California, San Francisco, California, USA
  1. Correspondence to : Dr Philip J Rosenthal, Department of Medicine, University of California, San Francisco, CA 94143, USA; philip.rosenthal{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMed


Malaria remains one of the greatest infectious burdens in the world.1 The RTS,S vaccine results from decades of research showing that human responses to the Plasmodium falciparum circumsporozoite protein can protect against malaria.2 Vaccine developments benefitted from adjuvant optimisation, with AS01 chosen for recent trials. RTS,S has been extensively studied in African children recently, with vaccine efficacy approximately 25–50% against both symptomatic and severe malaria, but efficacy lower in infants than in children and waning over time after immunisation.3–5 This report provides final follow-up data for a large phase III trial conducted at 11 sites in sub-Saharan Africa. It offers new insights into the long-term efficacy of …

View Full Text


  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.